Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection-Reference-Cited by-同舟云学术

Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection

Published:2023-11-10 Issue:1 Volume:103 Page:285-296
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Takenaka Katsuto,Fuji Shigeo,Matsukawa Toshihiro,Uchida Naoyuki,Kobayashi Takeshi,Tanaka Masatsugu,Ara Takahide,Ikegame Kazuhiro,Ozawa Yukiyasu,Kanda Yoshinobu,Sawa Masashi,Maruyama Yumiko,Fukuda Takahiro,Nakamae Hirohisa,Kimura Takafumi,Ogata Masao,Seo Sachiko,Atsuta Yoshiko,Matsuo Keitaro,Nakasone Hideki

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-023-05474-1.pdf

Reference40 articles.

1. Boeckh M, Murphy WJ, Peggs KS (2015) Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 21(1):24–29. https://doi.org/10.1016/j.bbmt.2014.11.002

2. Boeckh M, Ljungman P (2009) How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23):5711–5719

3. Ljungman P, Hakki M, Boeckh M (2010) Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin N Am 24(2):319–337

4. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN European Conference on Infections in Leukaemia g (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19(8):e260–e272. https://doi.org/10.1016/S1473-3099(19)30107-0

5. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M, Einsele H, Ferrant A, Lipton JH, Villano SA, Chen H, Boeckh M (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11(4):284–292. https://doi.org/10.1016/S1473-3099(11)70024-X

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus in haematopoietic cell transplantation - The troll is still there;Best Practice & Research Clinical Haematology;2024-09

2. Real-world experience with letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation: A multi-centre observational study;Journal of Infection;2024-08

3. Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice;Expert Review of Anti-infective Therapy;2024-03

4. Clinical impact of cytomegalovirus reactivation and immune reconstitution after allogeneic hematopoietic cell transplantation;Japanese Journal of Transplantation and Cellular Therapy;2024